A 23-year-old female patient with colicky abdominal pain, exacerbated post-prandially, presented to our hospital. Initial blood investigation and ultrasound abdomen were within normal limit except peripheral eosinophilia. Absolute eosinophil count was 2725/mm3. Patient did not have a history of atopy/allergy. Albendazole and ivermectin were administered on the initial presentation. Further investigation for peripheral eosinophilia yielded negative results, including stool parasite examination, Filarial polymerase chain reaction (PCR), perinuclear - antineutrophil cytoplasmic autoantibody, cytoplasmic – antineutrophil cytoplasmic autoantibody, peripheral smear for immature myeloid cell and tumor markers (cancer antigen -19-9, carcinoembryonic antigen, cancer antigen-125, alpha-fetoprotein). Contrast-enhanced computed tomography enterography revealed long segment circumferential mild thickening of distal duodenum and proximal jejunum (Fig. 1a, white arrows). However, endoscopy did not reveal any mucosal abnormality in duodenum and proximal jejunum (Fig. 1b). Random biopsy from distal duodenum and proximal jejunum (to rule out eosinophilic gastroenteritis) showed normal findings. No strongyloides were observed on duodenal biopsy (Fig. 1c). Repeat ultrasound of the abdomen revealed new onset moderate ascites. A diagnostic paracentesis revealed high protein, low serum ascites albumin gradient (SAAG) and highly cellular fluid. Ascitic fluid total count was 7800/mm3 and 98% eosinophils in differential count. Ascitic fluid cytology did not show any malignant cells (Fig. 1d). The diagnosis of serosal eosinophilic gastroenteritis was made. The patient was treated with prednisolone 40 mg for 15 days followed by tapering dose over eight weeks. The symptoms and ascites resolved after two weeks of steroid therapy. The patient remained asymptomatic at three-month follow-up.
WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.